PIPELINE-RSV International Trial. Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)- RSV International Immunisation Adaptive Platform Trial.

RSV (which stands for Respiratory Syncytial Virus) is an infection that causes cold-like symptoms and is most common during winter months. Most people with RSV infection get better by themselves but babies and younger children can become very poorly. About 1 in 15 infants with confirmed RSV within the first 12 months of life will be hospitalised, and a very small proportion will be seriously ill and may die.
Currently there are two different prevention options that can be used to prevent RSV infection in babies. One is a vaccine given to the mother during pregnancy, and the other is a monoclonal antibody given by injection to the baby. Although both prevention options work well on their own and are safe, neither provides 100% protection to the infant. It is not known whether giving both medicines, one to the mother in pregnancy and one to the infant, would provide better protection than giving only one medicine - this is what the PIPELINE-RSV study will look at.
PIPELINE-RSV-International will recruit about 1500 pregnant women from across Europe in UK, Switzerland, the Netherlands and Belgium. A parallel trial, PIPELINE-RSV-France, running in France will recruit about 1000 pregnant women in France; the protocols will align on key aspects and the data will be analysed together. The study will include three study groups with different prevention options used in each: (1) a vaccine given to the mother in pregnancy, (2) an injection given to the baby at the beginning of RSV season, or (3) both a vaccine given to the mother in pregnancy and an injection given to the baby at around 4 months of age. Each mother-baby pair will be randomly allocated to group by a computer. The numbers of babies in each of these groups who acquire RSV will be compared. In some countries only two of the three study groups may be available.
Pregnant women and their babies will be followed until the baby reaches 12 months of age. Information will be collected about medically-important side effects either the mother or the baby had from their medicine(s) and any symptoms of RSV the baby had. Visits with the mother and baby will occur at birth, and 4 and 12 months later; these will ideally be in-person at birth and at 12 months. The mother will complete questionnaires via a Web-based platform to report any non-routine in-person visits, once in pregnancy and after the baby is born twice a month or monthly (more often in the winter), to also report baby's symptoms, to report their trial experience when the baby is 4 and 12 months' old, and to provide their views on vaccination at birth, and when the baby is 4 and 12 months' old. If the baby develops symptoms that might be RSV, their mother or another caregiver will be asked to take a sample using a swab from the baby's nose or mouth, and to send it by post for testing to find out if the baby has RSV.
As well as the main research study, there are also some substudies. A questionnaire will be given to women who consent to take part, to find out their motivations for joining the study and how they prefer to receive information about taking part in studies. A small number of women will be asked to take part in a study to look at how mothers' and babies' immune systems respond to the two different study prevention options , and to investigate different ways of collecting samples from their babies. In addition, researchers will use data from the study to see whether giving both medicines is cost-effective compared with giving just one medicine.
The study might be adapted in the future to look at other medicines for preventing RSV infection, when they become available.

Start Date01 Sep 2025

Sponsor / Collaborator

Penta Global Blockchain Foundation, Inc.

NCT06546800

/ Active, not recruitingNot Applicable

SPECIAL INVESTIGATION FOR ABRYSVO INTRAMUSCULAR INJECTION -INVESTIGATION IN INDIVIDUALS AGED 60 YEARS OR OLDER-

This post-marketing study is a multicenter cohort study in individuals aged 60 years or older vaccinated with Abrysvo (RSV vaccine?designed to confirm the safety in individuals aged 60 years or older under actual clinical practice in Japan.

Start Date27 May 2025

Sponsor / Collaborator

Pfizer Inc.

NCT06866405

/ RecruitingPhase 3

A Phase 3 Study to Investigate the Safety, Tolerability, and Immunogenicity of Revaccinating Pregnant Participants During Subsequent Pregnancies and Persistence of Immunity of a Single Dose of a Bivalent Respiratory Syncytial Virus (RSV) Vaccine.

This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the blood of nonpregnant participants who had the vaccine before.

Start Date16 Apr 2025

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with RSVpreF

100 Translational Medicine associated with RSVpreF

100 Patents (Medical) associated with RSVpreF

158

Literatures (Medical) associated with RSVpreF

31 Dec 2025·Expert Review of Vaccines

Potential public health and economic impact of maternal vaccination with bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for the prevention of acute respiratory infection among infants in the United States

Article

Author: Shea, Kimberly M. ; Gessner, Bradford D. ; Averin, Ahuva ; Pugh, Sarah ; Weycker, Derek ; Atwood, Mark ; Quinn, Erin ; Cane, Alejandro ; Law, Amy W. ; Atwell, Jessica E.

BACKGROUND:

The U.S. Advisory Committee on Immunization Practices recommends use of bivalent stabilized prefusion F subunit vaccine (RSVpreF) among pregnant persons to protect their infants against lower respiratory tract illness due to RSV (RSV-LRTI).

RESEARCH DESIGN AND METHODS:

Using a cohort model depicting clinical outcomes and economic costs of RSV acute respiratory infection (RSV-ARI) among US infants from birth to age 1 year, we evaluated the impact of seasonally administered maternal RSVpreF versus no intervention. Outcomes included cases of medically attended RSV-ARI, RSV-related deaths, medical costs, and indirect costs. Costs were reported in 2023 US$.

RESULTS:

Among the 3.7 million US infants aged <12 months each year, a total of 1,148,967 RSV-ARI cases (hospital: 48,384; emergency department [ED]: 246,118; outpatient clinic [OC]: 854,465) were projected to occur, yielding total annual costs of $2.4 billion (direct: $1.7B; indirect: $0.7B). With 54.9% uptake, RSVpreF would prevent 89,908 cases (hospital: 10,308; ED: 20,538; OC: 59,062), corresponding with a $368 million decrease (direct: $286 M; indirect: $81 M) in total 1-year costs.

CONCLUSION:

Even with limited uptake and without considering benefits to pregnant persons or reductions in RSV-related sequelae, maternal vaccination with RSVpreF would substantially reduce the public health and economic burden of RSV-ARI in US infants.

31 Dec 2025·Human Vaccines & Immunotherapeutics

Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands

Article

Author: Atwood, Mark ; van den Boer, Jennie ; Langedijk, Annefleur C. ; van den Dungen, Floris ; Averin, Ahuva ; Smit, Lucy ; Law, Amy ; Quinn, Erin ; Harteveld, Lisette ; Mendes, Diana ; van Houten, Marlies

The European Medicines Agency has authorized two interventions to prevent lower respiratory tract disease due to respiratory syncytial virus (RSV-LRTD) in infants: nirsevimab, a monoclonal antibody, and bivalent stabilized prefusion F subunit maternal vaccine (RSVpreF). In the Netherlands, RSV-LRTD protection is recommended for all infants with nirsevimab given preferential recommendation over RSVpreF. We evaluated cost-effectiveness of various intervention strategies to prevent RSV in the Netherlands. We employed a cohort model to evaluate clinical and economic outcomes associated with RSV-LRTD during the first year of life among infants receiving RSVpreF with complementary nirsevimab and, alternatively, nirsevimab alone versus no intervention. Model inputs, based principally on Dutch data, include rates of disease, case-fatality, general mortality; disutility; and costs of interventions, medical care, treatment-related travel, and disease-associated work loss. Uptake of interventions assumed 70%; effectiveness was based on a published study using Phase III trial data. Analyses were conducted from the societal perspective using 2023 EUR; annual discount rates were 3% for costs and 1.5% for quality-adjusted life-years (QALYs). With no intervention, there were 10,482 RSV-LRTD cases with total associated costs of € 17.4M. Nirsevimab alone prevented 4,905 cases, yielding 100 QALYs; total costs increased by € 59.3M due to high intervention costs and cost-effectiveness was € 592,404/QALY (vs. no intervention). RSVpreF with complementary nirsevimab for infants prevented 4,723 cases, yielding 108 QALYs; total costs increased by € 35.5M and cost-effectiveness was € 329,187/QALY (vs. no intervention). Maternal RSVpreF with complementary nirsevimab was more cost-effective than nirsevimab alone.

31 Dec 2025·Human Vaccines & Immunotherapeutics

Budget impact of maternal vaccination with RSVpreF to protect privately insured infants in Dubai against respiratory syncytial virus

Article

Author: Zayed, Mostafa ; Joury, Jean ; Al Dallal, Sara ; Farghaly, Mohamed ; Law, Amy W. ; Kutrieb, Emily ; Averin, Ahuva ; Mendes, Diana ; Mahendiran, Ramya ; Quinn, Erin

Respiratory syncytial virus (RSV) manifesting as lower respiratory tract illness (LRTI; RSV-LRTI) represents a significant healthcare burden among infants in Dubai and worldwide. The novel bivalent stabilized prefusion F subunit vaccine (RSVpreF) for administration among pregnant women to protect infants against RSV-LRTI has been evaluated and approved for use in Dubai. We assessed the budget impact of year-round maternal RSVpreF use to prevent RSV-LRTI among privately insured non-Emirati infants living in Dubai. A deterministic cohort model was built to illustrate clinical and economic outcomes of RSV-LRTI among infants from birth to age 1 year for five annual birth cohorts. Model population comprised infants born to non-Emirati pregnant women; parameter values were estimated principally based on published sources using Dubai-specific data to the extent possible. Model outcomes included cases of disease (hospital, emergency department, outpatient clinic), disease-attributable deaths, and costs of disease and vaccination (in US$). Budget impact was reported in terms of overall cost and per-member per-year (PMPY) cost. With no intervention, there would be 23,267 RSV-LRTI cases (1,960 hospital; 5,655 emergency department 15,652 outpatient) and medical costs would total $11.5 M over 5 years. Targeting 10% of pregnant women with RSVpreF would prevent 855 cases and reduce infant medical care costs by $0.5 M. With vaccination costs estimated at $3.6 M, overall costs would increase by $3.1 M overall and $0.19 PMPY. Findings suggest that RSVpreF use among pregnant women would substantially reduce the clinical and economic burden of RSV-LRTI in infants, requiring an investment of just $0.19 PMPY by private health insurers.

387

News (Medical) associated with RSVpreF

23 Jul 2025

·www.businesswire.com

As RSV Season Approaches, the Federation of Medical Women of Canada Urges National Response to Protect Infants Across the Country

TORONTO--(BUSINESS WIRE)--Today, the Federation of Medical Women of Canada (FMWC) released its latest white paper through the Maternal RSV Task Force—a national group of experts in maternal, infant, and public health—highlighting the urgent need for equitable access to maternal RSV prevention across Canada. With the 2025–2026 RSV season approaching, the task force is calling for immediate action to protect infants, especially healthy, full-term newborns who account for the majority of severe RSV cases. Respiratory Syncytial Virus (RSV) is the leading cause of infant hospitalizations in Canada, with 1 in 50 infants hospitalized during their first year of life1. The RSV virus causes upper and lower respiratory tract infections (LRTI)2, and babies who develop LRTI in early childhood have almost double the risk of premature death from respiratory disease relative to unaffected individuals.3 Although two newly approved RSV immunization options have been authorized by Health Canada — a maternal vaccine RSVpreF (Abrysvo™, Pfizer) and a monoclonal antibody for infants nirsevimab (Beyfortus™, Sanofi) — access remains inconsistent across provinces and territories. Ontario is leading by covering both RSVpreF for pregnant women and pregnant people and nirsevimab for infants, yet provinces like B.C. only cover the older monoclonal antibody, palivizumab, for high-risk infants — leaving 98% of infants unprotected and at risk for RSV.4 “With two safe and effective immunization options now available, we have the tools to protect infants from RSV—but awareness, access, and equity remain critical challenges,” says Dr. Vivien Brown, Family Physician and Co-Chair of the FMWC Maternal RSV Task Force. “This white paper highlights the urgent need for national coordination, public funding, and ongoing education to ensure that every pregnant woman and pregnant person, regardless of where they live, can protect their infant from this serious and preventable disease.” The white paper outlines 13 short- and long-term recommendations to improve RSV prevention in Canada, including: Public funding for RSV immunization (maternal vaccine year-round; nirsevimab seasonally) Authorizing pharmacists to administer publicly funded vaccines Tailoring education for a range of healthcare providers, including midwives and pharmacists Engaging with manufacturers to clarify the predicted availability of immunization options Implementing a universal, national immunization registry Strengthening national guidance on vaccination and provincial implementation “This is fundamentally about health equity,” says Dr. Shelley Ross, Family Physician and Co-Chair of the FMWC Maternal RSV Task Force. “Our hope is that by providing a clear, evidence-based roadmap that outlines the steps we can take as a united healthcare system, we can close the gaps and ensure every infant in Canada has the opportunity to be protected from RSV, regardless of geography or circumstance.” The task force also launched RSVProtect.ca, a national hub for healthcare providers and the public, offering up-to-date information and comprehensive educational resources on RSV and RSV protection strategies. The FMWC urges pregnant women and pregnant people to speak with their healthcare providers about RSV prevention options and calls on policymakers to help close the access gap as the upcoming 2025–2026 RSV season begins. For more details on the FMWC Maternal RSV White Paper and its recommendations, please visit www.rsvprotect.ca. About FMWC The Federation of Medical Women of Canada (FMWC) is a national organization recognized for its leadership and advocacy for women's evolving health. We are committed to promoting the well-being and health of women and women-identifying individuals both within the medical profession and society at large. The FMWC has a 100-year history in Canada, is a member of the non-governmental organization (NGO) section of the Department of Global Affairs at the United Nations (UN) and is a member of the Medical Women's International Association (MWIA), making us a part of the Economic and Social Council of the UN (ECOSO). For more information, please visit: www.fmwc.ca. 1 Government of Canada. Respiratory syncytial virus (RSV) vaccines: Canadian Immunization Guide. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian- immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html. Updated May 14, 2025. Accessed May 21, 2025. 2 Sanchez-Martinez A, Moore T, Freitas TS, et al. Recent advances in the prevention and treatment of respiratory syncytial virus disease. J Gen Virol. 2025;106(4). doi: 10.1099/jgv.0.002095 3 Zar HJ, Cacho F, Kootbodien T, et al. Early-life respiratory syncytial virus disease and long-term respiratory health. Lancet Respir Med. 2024;12(10):810-821. 4 Paes B, Brown V, Courtney E, et al. Optimal implementation of an Ontario nirsevimab program for respiratory syncytial virus (RSV) prophylaxis: Recommendations from a provincial RSV expert panel. Hum Vaccin Immunother. 2024;20(1):2429236.

VaccineClinical Study

14 Jul 2025

·www.pharmaceutical-technology.com

GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients

Broader label coverages for Pfizer and Moderna’s vaccines mean they have made in-roads into GSK’s RSV dominant market share. MAXSHOT.PL via Shutterstock. GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the disease. GSK’s Arexvy is already approved in the US for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk. If the latest regulatory submission is approved by the FDA, the vaccine will have indications in those aged 18 years and above. A decision by the FDA is expected in H1 2026. GSK’s application is based on a Phase IIIb trial (NCT06389487) that produced comparable results to data from the Phase III programme that supported the initial approval of the vaccine in the US. A single dose of the vaccine in adults aged 18-49 at increased risk of RSV-LRTD elicited robust immune responses that were non-inferior to those observed in adults aged 60 and above. Safety data was also in line with previous results, with the most common adverse events being local pain, fatigue, muscle ache, and headache, all of which were short-lasting. The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent LRTD in individuals aged 18 to 59 at increased disease risk. The broader label coverages for Abrysvo and mRESVIA mean Pfizer and Moderna have made in-roads into GSK’s RSV dominant market share, courtesy of Arexvy’s higher sales in older age groups. Arexvy initially captured a larger market share due to its stronger contracts with retail pharmacies and slightly earlier approval in the US market. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence The RSV market is one of the most lucrative in the pharmaceutical industry. Around 64 million people of all ages globally every year are impacted by RSV, a common respiratory virus that causes seasonal infections such as the flu. It is also a leading cause of pneumonia and death in infants and older adults. The global RSV market is set to reach $6.3bn in value by 2030, according to analysis by GlobalData. US vaccine pressures Despite vying for RSV market share, all three companies are operating within a highly pressurised vaccine landscape in the US. Revenue for Arexvy, Abrysvo, and mRESVIA in 2024 was significantly impacted by the tightening of US RSV vaccine recommendations, which led to reduced vaccination rates. FDA approvals do not automatically mean shots enter national immunisation schedules. That is instead recommended by the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP). A brief boost came in April, after the ACIP expanded the eligible at-risk group to people aged 50 and older. However, changes to the panel made by US health secretary Robert F Kennedy (RFK) Jr have ushered in new uncertainty surrounding the future of vaccines in the US. RFK Jr controversially axed the entire ACIP panel in June, replacing it with well-known vaccine sceptics and individuals lacking vaccine knowledge. The move has cast doubts on how immunisation recommendations will be voted on going forward, with infectious disease experts concerned about the consequences to public health. Pharmaceutical Technology Excellence Awards - Have you nominated? Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact . This is your chance to showcase your achievements, highlight industry advancements , and gain global recognition . Don't miss the opportunity to be honoured among the best - submit your nomination today! Nominate Now

VaccinePhase 3Clinical ResultDrug Approval

03 Jul 2025

·www.biospace.com

Kennedy Follows RSV Recommendations of ACIP Members He Fired

iStock, EyeEm Mobile GmbH Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are at risk of severe disease. Health and Human Services Secretary Robert F. Kennedy Jr. has signed off on the broader use of respiratory syncytial virus vaccines—in line with the recommendations of the CDC vaccine advisors whom he ousted last month. In April, the CDC’s Advisory Committee on Immunization Practices recommended expanding the use of RSV vaccines to adults aged 50 through 59 years who are at a higher risk of severe infection. Previous guidelines only endorsed the shot for high-risk older adults aged 60 to 74 and for all seniors 75 and up. “With no current CDC Director and pending confirmation of a new CDC Director, this recommendation was adopted by the HHS Secretary on June 25, 2025,” according to an update to the CDC’s website . The broader use of RSV vaccines in older adults “is now an official recommendation of the CDC.” Kennedy has also signed off on the ACIP’s endorsement of GSK’s meningococcal vaccine Penmenvy, which the FDA approved in February. There are currently three commercial RSV vaccines. First to market in May 2023 was GSK’s Arexvy , which is indicated for older adults 60 and up and at-risk people 50 through 59 years. Following a month later was Pfizer’s Abrysvo, available for use in patients 60 and above, as well as at-risk adults 18 through 59 years. Abrysvo can also be used in pregnant women 32 through 36 weeks of gestation. Moderna also has an RSV vaccine. The mRNA-based mRESVIA is also approved for older adults 60 and up, as well as at-risk younger adults 18 through 59 years. The RSV recommendations were made by the CDC’s previous vaccine advisory panel, which Kennedy completely purged last month in a move that he claimed would help “reestablish public confidence in vaccine science.” Experts have told BioSpace that despite Kennedy’s misgivings about supposed industry interference in the ACIP, conflicts of interest have largely been well-managed by the CDC, which directs its panelists to recuse themselves from voting on matters relevant to their conflicts. Kennedy soon reconstituted the ACIP, but this time with fewer members, several of whom are documented vaccine critics. Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research, has also spoken of restoring the public’s confidence in vaccines. One such initiative is the FDA’s new risk-based approach to COVID-19 vaccine approval. It recently came to light that this has caused some friction within the agency’s ranks. On May 30, the FDA’s product review committee recommended the approval of Moderna’s COVID-19 shot MNEXSPIKE for patients 12 years and up who have previously been inoculated with a coronavirus vaccine. That same day, however, Prasad put out his own memo disagreeing with the committee’s conclusions, instead endorsing a more limited use for the shot that included blanket use only for those 65 and up. For people 12 through 64 years, Prasad wanted MNEXSPIKE indicated only in the presence of an underlying condition that could heighten the risk of severe COVID-19 outcomes. “I am unable to conclude that the product has improved safety or reduced reactogenicity for younger individuals at low risk of severe disease,” he wrote in his memo. “Furthermore, uncommon risks, including those that might be novel to MNEXSPIKE, cannot be ruled out.” In a statement to Endpoints News , a spokesperson for HHS defended Prasad’s action, contending that he is “correcting course with data, with transparency, and with the courage to say what others won’t. That’s how trust in science is rebuilt.” The FDA approved MNEXSPIKE on May 31—a day after the back-and-forth at CBER—with a label that reflects Prasad’s more restricted recommendations.

VaccineDrug ApprovalmRNA

100 Deals associated with RSVpreF

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pneumonia due to respiratory syncytial virus	European Union	Pfizer Europe MA EEIG	23 Aug 2023
Pneumonia due to respiratory syncytial virus	Iceland	Pfizer Europe MA EEIG	23 Aug 2023
Pneumonia due to respiratory syncytial virus	Liechtenstein	Pfizer Europe MA EEIG	23 Aug 2023
Pneumonia due to respiratory syncytial virus	Norway	Pfizer Europe MA EEIG	23 Aug 2023
Respiratory Syncytial Virus Infections	United States	Pfizer Inc.	31 May 2023
Lower Respiratory Tract Infections	Canada	Pfizer Canada ULC	04 Jan 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Herpes Zoster	Phase 3	United States	Pfizer Inc.	04 Apr 2025
Influenza, Human	Phase 3	Australia	Pfizer Inc.	13 Apr 2022
Respiratory Tract Infections	Phase 3	United States	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Japan	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Argentina	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Australia	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Brazil	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Canada	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Chile	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Denmark	Pfizer Inc.	17 Jun 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04424316 (MATISSE, CTgov)	Phase 3	Respiratory Tract Infections	14,727	RSVpreF (Infant Participants: RSVpreF)	cetcwdriwj = zhhntrkbnj imvvwhonyq (euqpkttjsc, xgriowrukv - nmlmspywfq) View more	-	11 Feb 2025
				placebo+RSVpreF (Infant Participants: Placebo)	cetcwdriwj = khhzcksazr imvvwhonyq (euqpkttjsc, wdykxfczww - ieiummuzjw) View more
NCT04424316 (MATISSE, Pubmed \| Obstet Gynecol)	Phase 3	Obstetric Labor, Premature	-	Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVpreF)	seobemkskh(hovrzztlff) = no clinically significant increase in adverse events of special interest, including preterm birth, low birth weight, or neonatal hospitalization, was observed among pregnant people in the overall analysis roimkziooc (qvhszuhyct ) View more	Positive	02 Jan 2025
				Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine (Placebo)
NCT05886777 (CTgov)	Phase 2	COVID-19 \| Infectious Lung Disorder	1,142	QIV+RSVpreF (Group 1: [RSVpreF + BNT162b2] + QIV)	obzjbmnpcx = drgoczjdpn llbkapxwkf (igryjyindb, yzkburhlny - iftpflgefq) View more	-	18 Dec 2024
				Placebo+BNT162b2+RSVpreF (Group 2: [RSVpreF+BNT162b2] + Placebo)	obzjbmnpcx = dtrdsssank llbkapxwkf (igryjyindb, sajfzryoui - wnqttipynd) View more
NCT05788237 (CTgov)	Phase 1	Influenza, Human	508	RSVpreF+qIRV (SSA: Group 1: RSVpreF + qIRV)	yabdhmlzyl = hkyusbttqr mzkcbwnuxp (uwoqmupene, mwqkqxxxqn - lskclrbmuy) View more	-	22 Nov 2024
				qIRV (SSA: Group 2: qIRV)	yabdhmlzyl = atcsmdkjrl mzkcbwnuxp (uwoqmupene, sahvvlrvfy - mfeucjczqj) View more
NCT05842967 (MONeT, PipelineReview) Manual	Phase 3	Respiratory Syncytial Virus Infections	203	ABRYSVO	vbkgexxayb(ggqruykxsl) = ABRYSVO was well-tolerated during the trial, showing a safety profile consistent with findings from other studies of the vaccine. yyofzjoraz (fjxjjebvdz ) View more	Positive	12 Aug 2024
NCT04785612 (Phase 2a study, CTgov)	Phase 2	Respiratory Syncytial Virus Infections	70	RSVPreF (RSVPreF)	rscdrsgwjc(rbfudkwlaj) = pnkzcmyrfi dylutxntgx (pirykdwlqb, dduomgfipw - dwrfnnuuyz) View more	-	07 Aug 2024
				Placebo (Placebo)	rscdrsgwjc(rbfudkwlaj) = vukrggslhc dylutxntgx (pirykdwlqb, mjczvphhti - zchtezfxos) View more
NCT04424316 (MATISSE, Pubmed)	Phase 3	Respiratory Syncytial Virus Infections	-	RSVpreF vaccine	bcmottvwlb(pxjzuwppxa) = qavmjyzafa yrsiehzrpy (acurbxmrwt ) View more	Positive	08 Jun 2024
				bivalent RSVpreF maternal vaccination (Placebo)	bcmottvwlb(pxjzuwppxa) = sxweafysws yrsiehzrpy (acurbxmrwt ) View more
NCT05842967 (MONeT, Corporate Publications) Manual	Phase 3	Pulmonary Disease, Chronic Obstructive \| Asthma \| Diabetes Mellitus ... View more	-	ABRYSVO	efthetufdo(nktfonruiw) = Participants demonstrated RSV-A and RSV-B subgroup neutralizing responses non-inferior to the response seen in the Phase 3 (NCT05035212) RENOIR study of ABRYSVO in more than 34,000 adults aged 60 or older where vaccine efficacy was previously demonstrated. xqtwhksnok (eabgcnvqmz ) Met View more	Positive	09 Apr 2024
NCT05035212 (RENOIR, Biospace) Manual	Phase 3	Respiratory Syncytial Virus Infections	-	ABRYSVO (three or more symptoms)	ncmmwuopps(cofwopesui) = cqplqdutzp bpkzmonhju (vwuwknlaqg, 51.4 - 91.1) View more	Positive	29 Mar 2024
				ABRYSVO (two or more symptoms)	ncmmwuopps(cofwopesui) = ontfjaciue bpkzmonhju (vwuwknlaqg, 34.7 - 70.4) View more
NCT04424316 (MATISSE, NEWS) Manual	Not Applicable	Respiratory Syncytial Virus Infections	-	Abrysvo (first 90 days after birth)	xxstaohxio(nhozhcrkfw) = bxwqldhkna vmdofprtxl (xagslqehqh )	Positive	29 Nov 2023
				Abrysvo (within 180 days)	xxstaohxio(nhozhcrkfw) = ndpmwowljr vmdofprtxl (xagslqehqh )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

RSVpreF

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation